Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Mechanisms of trastuzumab resistance and their clinical implications.

Lan KH, Lu CH, Yu D

Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030. dyu@mdanderson.org.

Trastuzumab (Herceptintrade mark) is an excellent model of rationally designed targeted cancer treatment. However, less than 35% of patients with ErbB2-positive breast tumors respond to trastuzumab as a single agent, and 2-5% of trastuzumab-treated patients suffer from severe side effects, including cardiac dysfunction. Recent progress in understanding the mechanisms of trastuzumab antitumor function and cellular defects leading to trastuzumab resistance is summarized. Also explored is the potential of combination therapies for reversing trastuzumab resistance.

Published 29 December 2005 in Ann N Y Acad Sci, 1059: 70-5.
Full-text of this article is available online (may require subscription).

© 2004-2008 Herceptin Research Today. All Rights Reserved.